Stelis Biopharma Partners with Bio-Scaffold International for 3-D Printing Device

Stelis Biopharma, previously known as Agila Biotech, has begun a research collaboration partnership with Bio-Scaffold International Pte Ltd. (BSI), a Singapore-based start-up company, to develop a bone morphogenetic protein (BMP) and stem cell loaded 3-D printed device for applications in orthopedics cosmetology/plastic and reconstructive surgery and dentistry.

The Research will be jointly directed by Anand Iyer, Ph.D., JD, CEO of Stelis Biopharma and Margam Chandrasekaran, Ph.D., CEO and chief scientist of BSI. Each company will bear the cost of its contribution to the joint research collaboration.

BSI has expertise in the application of 3-D printing technology for the development of biocompatible scaffolds. Stelis is a biotechnology company whose research and development efforts include the development of drug and stem cell loaded devices for the treatment of various medical conditions. Scientists from Stelis and BSI have developed a framework for initial research collaboration which would include working on multiple areas such as BMP-2/7 heterodimer loaded scaffold for orthopedic applications and BMP2/ BMP7 loaded scaffolds for spinal fusion.

Stelis Biopharma is building a state-of-the-art facility in Bangalore, India, where the company is headquartered, to research and develop biotherapeutic drugs and devices including biosimilars, biobetters, NBEs, novel formulations and drug loaded devices. The company is also building a fully integrated manufacturing facility at Bio-Xcell’s biotechnology park in Nusajaya, within the Iskandar region of Johor, Malaysia, for the manufacture of biotherapeutics and devices.